Öz

 

Objective: In failed cases treated with the endoscopic sub-ureteric injection method, no residue from the previous injection material was found during cystoscopy at the second injection. The clinical observation of an increased incidence of recurrent reflux in girls than in boys reminds us that bladder gender may influence the stability of the injection material. The aim of the study was to determine whether there is a gender-related difference in the durability of the subureteric injection material.

Material and Methods: Twenty male and female Wistar-Albino rats were evenly divided into four groups. The experimental group received a submucosal injection of 0.1cc dextranomer hyaluronic acid copolymer (Dexell®) into the bladder. In addition, the control group received 0.1cc of 0.9% NaCl. Tissue hyaluronidase activity was measured biochemically using the ELISA method. The injection sites were assessed histopathologically and immunohistochemically with CD31 and CD34 Rabbit Monoclonal Antibodies.

Results: Biochemically, tissue hyaluronidase activity in female groups was statistically significantly higher than in males. Histopathologically, there were no significant differences between the genders or between the experimental and control groups in relation to fibrosis formation. Regarding immunohistochemistry, angiogenesis was statistically significantly higher in all females, regardless of whether they were in the study or control group, compared to males. Concerning progenitor cell activity, there is no difference between the genders, whereas the difference between the study and control groups was significant.

Conclusion: Biochemically, higher hyaluronidase activity in the female rat bladder may cause a faster breakdown of the hyaluronic acid compound in the injection material. The high permeability of inflammatory cells in the female rat bladder, as detected histochemically, may accelerate the destruction process with the aid of lytic enzymes in these cells.

Anahtar Kelimeler: Bladder, children, gender, vesicoureteral reflux

Kaynakça

  1. Brock WJ CD. The Kelalis–King–Belman: Textbook of Clinical Pediatric Urology. In: Docimo SG, Canning DA KA, ed. The Kelalis–King–Belman: Textbook of Clinical Pediatric Urology. 6th ed. CRC Press; 2019:708-720.
  2. Miyakita H, Hayashi Y, Mitsui T, et al. Guidelines for the medical management of pediatric vesicoureteral reflux. Int J Urol. 2020;27(6):480-90. https://doi.org/10.1111/iju.14223
  3. Scalabre A, Demède D, Mouriquand P. Vesicoureteric reflux: open and minimally invasive treatment. In: Azizkhan RZG, Von Allmen D, Weber TR, eds. Operative Pediatric Surgery. 8th ed. London: CRC Press; 2023:1757–1794.
  4. Vesicoureteral Reflux Guideline - American Urological Association. Accessed March 7, 2023. https://www.auanet.org/guidelines-and-quality/guidelines/vesicoureteral-reflux-guideline
  5. Thergaonkar RW, Hari P. Current Management of Urinary Tract Infection and Vesicoureteral Reflux. Indian J Pediatr. 2020;87(8):625-32. https://doi.org/10.1007/s12098-019-03099-9
  6. Tiboni SG, Bethell GS, Davidson JR, Farrugia MK. Factors Influencing Success in Endoscopic Treatment of Grade 4-5 Primary Vesicoureteric Reflux (VUR) in Infancy and Childhood. J Pediatr Surg. 2025;60(3): 162157. https://doi.org/10.1016/j.jpedsurg.2025.162157
  7. Khoury AE, Wehbi E. Management Strategies for Vesicoureteral Reflux. in: Elsevier, ed. Campbell-Walsh-Wein Urology. 2021:489-517.
  8. Sabetkish S, Mohseni MJ, Sabetkish N, Kajbafzadeh AM. Local tissue reaction and histopathological characteristics of three different bulking agents: a rabbit model. International Braz J Urol. 2021;47(2):322-32. https://doi.org/10.1590/s1677-5538.ibju.2020.0171
  9. Weber GC, Buhren BA, Schrumpf H, Wohlrab J, Gerber PA. Clinical applications of hyaluronidase. In: Labrou N, ed. Therapeutic Enzymes: Function and Clinical Implications. Cham: Springer; 2019:255–77. https://doi.org/10.1007/978-981-13-7709-9_12
  10. Goodman ZD. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol. 2007;47(4):598-607. https://doi.org/10.1016/j.jhep.2007.07.006
  11. Horak ER, Leek R, Klenk N, et al. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet. 1992;340:1120-4. https://doi.org/10.1016/0140-6736(92)93150-L
  12. Izol V, Kuyucu Y, Acikalin A, et al. Evaluation of the Intravesical Ureters after Failed Endoscopic Treatment of Vesicoureteral Reflux with Dextranomer/Hyaluronic Acid in Children via Light and Transmission Electron Microscopic Analysis. A Matched Case-Control Study. Urol J 2019;16(3):279-84. https://doi.org/10.22037/uj.v16i3.4281
  13. Elder JS, Diaz M, Caldamone AA, et al. Endoscopic therapy for vesicoureteral reflux: a meta-analysis. I. Reflux resolution and urinary tract infection. J Urol. 2006;175(2):716-22. https://doi.org/10.1016/S0022-5347(05)00210-7
  14. Kirsch AJ, Perez-Brayfield M, Smith EA, Scherz HC. The Modified Sti̇n Procedure to Correct Vesicoureteral Reflux:Improved Results with Submucosal Implantation the Intramural Ureter. Journal of Urology. 2004;171(6 Part 1):2413-6. https://doi.org/10.1097/01.ju.0000127754.79866.7f
  15. Roupakias S, Sinopidis X, Spyridakis I, Tsikopoulos G, Karatza A, Varvarigou A. Endoscopic Injection Treatment of Vesicoureteral Reflux in Children: Meeting with the Factors Involved in the Success Rate. Acta Medica (Hradec Kralove). 2021;64(4):193-9. https://doi.org/10.14712/18059694.2022.1
  16. Silva JMP, Oliveira EA, Diniz JSS, et al. Gender and vesico-ureteral reflux: A multivariate analysis. Pediatric Nephrology. 2006;21(4):510-6. https://doi.org/10.1007/s00
  17. Nordenström J, Sjöström S, Sillén U, Sixt R, Brandström P. The Swedish infant high-grade reflux trial: UTI and renal damage. J Pediatr Urol. 2017;13(2):146-54. https://doi.org/10.1016/j.jpurol.2016.12.023
  18. Dogan HS, Altan M, Citamak B, Bozaci AC, Koni A, Tekgul S. Factors affecting the success of endoscopic treatment of vesicoureteral reflux and comparison of two dextranomer based bulking agents: Does bulking substance matter? J Pediatr Urol. 2015;11(2):90.e1-90.e5. https://doi.org/10.1016/j.jpurol.2014.12.009
  19. Lokeshwar VB, Cerwinka WH, Lokeshwar BL. HYAL1 Hyaluronidase: A Molecular Determinant of Bladder Tumor Growth and Invasion. Accessed September 6, 2022. www.aacrjournals.org
  20. Liang Z, Zhang Q, Wang CH, et al. Hyaluronic acid/ Hyaluronidase as biomarkers for bladder cancer: a diagnostic meta-analysis. Neoplasma. 2017;64:901-8. https://doi.org/10.4149/neo_2017_612
  21. Alkan M, Ciftci AO, Talim B, Senocak ME, Caglar M, Buyukpamukcu N. Histological response to injected dextranomer-based implant in a rat model. Pediatr Surg Int. 2007;23(2):183–7. https://doi.org/10.1007/s00383-006-1818-1
  22. Broderick K, Thompson JH, Khan AR, Greenfield SP. Giant cell reaction with phagocytosis adjacent to dextranomer-hyaluronic acid (Deflux) implant: Possible reason for Deflux failure. J Pediatr Urol. 2008;4(4):319-21. https://doi.org/10.1016/j.jpurol.2007.11.003
  23. Kajbafzadeh AM, Sabetkish S, Khorramirouz R, Sabetkish N. Comparison of histopathological characteristics of polyacrylate polyalcohol copolymer with dextranomer/hyaluronic acid after injection beneath the bladder mucosa layer: a rabbit model. Int Urol Nephrol. 2017;49(5):747-52. https://doi.org/10.1007/s11255-017-1540-z

Telif hakkı ve lisans

Telif hakkı © 2026 Yazar(lar). Açık erişimli bu makale, orijinal çalışmaya uygun şekilde atıfta bulunulması koşuluyla, herhangi bir ortamda veya formatta sınırsız kullanım, dağıtım ve çoğaltmaya izin veren Creative Commons Atıf Lisansı (CC BY) altında dağıtılmıştır.

Nasıl atıf yapılır

1.
Ünluü Ballı SE, Surer H, Secken P, Bahadır GB, Şimşek G, Demirbag S, et al. Gender effect on dextranomer hyaluronic acid injection material durability: A rat bladder model. Turk J Pediatr Dis. 2026;Early View:1-6. https://doi.org/10.12956/TJPD.2025.1239